IP Library › Granted Patent US 12,220,411
Granted Patent B1
US 12,220,411 · App. 18/692,452 · Granted Feb 11, 2025

Application of PTGDS inhibitor in preparation of drug for treating cataracts

Inventors: Jin Li (Wenzhou, CN); Jiasheng Liu (Wenzhou, CN); Yitong Xu (Wenzhou, CN); Mengchao Zhu (Wenzhou, CN); Haisen Sun (Wenzhou, CN)
Assignee: THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY
A61K31/454A61P27/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,220,411
App. No.
18/692,452
Granted
Feb 11, 2025
Kind
B1
Abstract

Application of a PTGDS inhibitor in preparation of a drug for treating cataracts is provided. As an effective and selective PTGDS inhibitor, AT-56 competitively inhibits production of PGD2 by occupying a catalytic site of PTGDS. The PTGDS catalyzes synthesis of the PGD2 to cause an oxidative stress injury of human lens epithelial cells, thereby promoting occurrence and development of aging and opacity of a lens. By reducing apoptosis caused by the oxidative stress injury, a degree of the cataracts can be effectively reduced.

Claims (2)

1. A method for treating age-related cataracts comprising administering 7-10 UM of the prostaglandin D synthase (PTGDS) inhibitor 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl) butyl]-piperidine (AT-56).

2. A method for treating an oxidative stress injury of lens epithelial cells comprising administering 7-10 μM of the prostaglandin D synthase (PTGDS) inhibitor 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]-piperidine (AT-56).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2024
From: LI, JIN; LIU, JIASHENG; XU, YITONG; ZHU, MENGCHAO; SUN, HAISEN
To: THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY
Reel/Frame 066824/0527 →
Priority Claims (1)
CN 202310914152.1 · Jul 25, 2023 · national
References Cited (12)
US 20150285800A1 · Ragolia · 2015 [cited by examiner]
US 20160228584A1 · Lin et al. · 2016 [cited by applicant]
CN 101039920A · 2007 [cited by applicant]
CN 101146770A · 2008 [cited by applicant]
CN 101495449A · 2009 [cited by applicant]
JP H04253909A · 1992 [cited by applicant]
WO WO9501350A1 · 1995 [cited by applicant]
Irikura, Daisuke, et al., “Biochemical, Functional, and Pharmacological Characterization of AT-56, an Orally Active and Selective Inhibitor of Lipocalin-type Prostaglandin D Synthase,” [cited by applicant]
Bauer, MD, Gregor, et al., “Lipocalin-like Prostaglandin D Synthase (L-PGDS) Concentration in Aqueous Humour in Patients With Open-angle Glaucoma,” [cited by applicant]
Gao, Jie, et al., “Research progress on the application of non steroidal anti-inflammatory drugs in cataract surgery,” [cited by applicant]
Dong, Dongsheng, et al., “Study on the biosynthesis of prostaglandins in the lens of galactose induced cataracts in rats,” [cited by applicant]
Gao, Yuan, et al., “The relationship between cyclooxygenase-2 and eye diseases,” [cited by applicant]